- Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).
- AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting
- AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting
- AbbVie’s Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting
- AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
- LSP licensee AbbVie Receives EMA and FDA Orphan Drug Designation for Investigational Compound ABT-414 in the Treatment of Glioblastoma Multiforme
- AbbVie Presents Results from Study of Investigational Compound in Patients with Glioblastoma at the American Society of Clinical Oncology’s 50th Annual Meeting
- Life Science Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of ABT-806 for the Treatment of Cancer
- Life Science Pharmaceuticals Enters Into Agreement with Abbott to Develop Antibody 806
